External broker reports(aggregated public sources), Rong Viet Securities

Rong Viet Securities

External broker reports(aggregated public sources)

RongViet is proud to have a research team of experienced and trustworthy people whose works are at all time governed by the codes of objectivity, integrity and client's best interest.

Looking at relevant, up-to-date information from multiple perspectives with the support of intensive data and analyses, RongViet's research is effective, practical and widely used for investing purposes.

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Imexpharm Pharmaceutical Jsc / Equity Bottom-Up

<ul><li>Net revenue and NPATMI were VND 491 bn (+2% YoY) and VND 62 bn (-20% YoY), respectively, achieving 21% and 18% of the annual plan.</li><li>Gross revenue of the ETC and OTC were VND 270 bn (+52% YoY) and VND 260 bn (-13% YoY), respectively.</li><li>The GPM decreased by 4 pps due to the depreciation expenses incurred by the IMP 4 factory (which became operational in 2H2023).</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Net revenue and NPATMI were VND 491 bn (+2% YoY) and VND 62 bn (-20% YoY), respectively, achieving 21% and 18% of the annual plan.Gross revenue of the ETC and OTC were VND 270 bn (+52% YoY) and VND 260 bn (-13% YoY), respectively.The GPM decreased by 4 pps due to the depreciation expenses incurred by the IMP 4 factory (which became operational in 2H2023).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

IMEXPHARM CORPORATION - Expect Profit Recovery in Second Half of 2024

Vietnam

Imexpharm Pharmaceutical JSC is a pharmaceutical Company. The Company manufactures pharmaceutical products, traditional medicines as well as trades drugs, raw materials for medicine production, and medical equipment. Imexpharm also offers rental services of warehouse for medicine storage and produces and trades nutritious foods.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00